Aclaris Therapeutics, Inc. $ACRS Position Increased by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp significantly increased its position in Aclaris Therapeutics by 223.3%, acquiring an additional 121,500 shares and bringing its total holdings to 175,900 shares worth approximately $269,000.
• Aclaris Therapeutics reported a revenue of $1.78 million in its latest earnings, surpassing analysts' expectations of $1.34 million, though it still posted an EPS of (0.13).
• Institutional investors now own 98.34% of Aclaris Therapeutics' stock, indicating strong institutional interest in the company.

OMERS ADMINISTRATION Corp lifted its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 223.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 175,900 shares of the biotechnology company's stock after acquiring an additional 121,500 shares during the period. OMERS ADMINISTRATION Corp owned 0.16% of Aclaris Therapeutics worth $269,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of ACRS. Raymond James Financial Inc. purchased a new stake in Aclaris Therapeutics during the fourth quarter valued at about $383,000. Dimensional Fund Advisors LP increased its holdings in shares of Aclaris Therapeutics by 211.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 239,595 shares of the biotechnology company's stock valued at $594,000 after purchasing an additional 162,785 shares during the period. Northern Trust Corp increased its holdings in shares of Aclaris Therapeutics by 37.7% in the 4th quarter. Northern Trust Corp now owns 175,175 shares of the biotechnology company's stock valued at $434,000 after purchasing an additional 47,950 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Aclaris Therapeutics in the 4th quarter valued at about $327,000. Finally, Bank of America Corp DE increased its holdings in Aclaris Therapeutics by 2,246.3% in the fourth quarter. Bank of America Corp DE now owns 205,465 shares of the biotechnology company's stock worth $510,000 after buying an additional 196,708 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Price Performance

NASDAQ:ACRS opened at $2.07 on Friday. Aclaris Therapeutics, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $5.17. The stock has a market capitalization of $224.24 million, a PE ratio of -1.51 and a beta of 0.27. The business's 50-day simple moving average is $1.66 and its 200-day simple moving average is $1.55.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.The firm had revenue of $1.78 million for the quarter, compared to analysts' expectations of $1.34 million. On average, research analysts expect that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ACRS shares. Scotiabank decreased their target price on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research report on Friday, May 9th. Piper Sandler began coverage on Aclaris Therapeutics in a research report on Thursday, July 10th. They issued an "overweight" rating and a $6.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, June 25th. Finally, Wedbush reiterated an "outperform" rating and set a $8.00 price objective on shares of Aclaris Therapeutics in a research note on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $8.71.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.